Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Keros Therapeutics (KROS) Revenue: 2019-2025

Historic Revenue for Keros Therapeutics (KROS) over the last 5 years, with Sep 2025 value amounting to $14.3 million.

  • Keros Therapeutics' Revenue rose 3575.77% to $14.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $246.7 million, marking a year-over-year increase of 37798.31%. This contributed to the annual value of $3.5 million for FY2024, which is 2250.99% up from last year.
  • According to the latest figures from Q3 2025, Keros Therapeutics' Revenue is $14.3 million, which was down 21.50% from $18.2 million recorded in Q2 2025.
  • In the past 5 years, Keros Therapeutics' Revenue registered a high of $211.2 million during Q1 2025, and its lowest value of -$1,000 during Q1 2021.
  • For the 3-year period, Keros Therapeutics' Revenue averaged around $27.5 million, with its median value being $388,000 (2024).
  • Data for Keros Therapeutics' Revenue shows a peak YoY spiked of 2,000,100.00% (in 2021) over the last 5 years.
  • Quarterly analysis of 5 years shows Keros Therapeutics' Revenue stood at $20.0 million in 2021, then surged by 1,800,100.00% to $18.0 million in 2022, then reached $143,000 in 2023, then soared by 2,027.27% to $3.0 million in 2024, then spiked by 3,575.77% to $14.3 million in 2025.
  • Its Revenue was $14.3 million in Q3 2025, compared to $18.2 million in Q2 2025 and $211.2 million in Q1 2025.